McMillan Shakespeare (ASX:MMS) Posts Strong Full Year Results, Is It Fully Priced?
McMillan Shakespeare (ASX:MMS) is back in focus after releasing full year results to June 30, 2026, reporting higher sales, revenue, and net income, alongside a fully franked A$0.70 per share dividend announcement.
At a share price of A$20.15, McMillan Shakespeare has delivered a year to date share price return of 17.42% and a 1 year total shareholder return of 12.84%. The 3 year and 5 year total shareholder returns of 48.25% and 140.50% point to longer term momentum that recent earnings and dividend news are now helping to refresh in the short term, despite a softer 7 day share price move.
Scan beyond McMillan Shakespeare and compare this earnings and dividend story with a curated 8 dividend fortresses that meet similar income focused criteria.
Following that share price rise and the latest A$0.70 dividend, McMillan Shakespeare now trades only slightly below the A$20.57 analyst target, yet remains at a much steeper discount to some fair value estimates. Which reference point should investors use as the primary anchor for valuation?
Most Popular Narrative: 2% Undervalued
McMillan Shakespeare closed at A$20.15 compared with a widely followed fair value estimate of A$20.57 that builds in modest revenue and earnings growth supported by higher margins.
Ongoing investment and success in digital and AI-enabled platforms, such as MyMaxxia, Oly, and automation in PSS, are driving significant productivity improvements (increased customers per FTE, reduced cost-to-income ratio, streamlined processes). This should enhance MMS's net margins and support long-term earnings growth.
Read the complete narrative. Read the complete narrative.
Want to understand why this fair value only sits slightly above today’s price yet still assumes higher profitability? The narrative leans on steadier revenue, richer margins, and a tighter share count to justify that number. Curious which of those levers does the heavy lifting and how much optimism is priced in.
Result: Fair Value of A$20.57 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this McMillan Shakespeare narrative can shift quickly if regulatory changes around NDIS or salary packaging tighten, or if competition pressures margins more than expected.
Find out about the key risks to this McMillan Shakespeare narrative.
Next Steps
Given the mix of optimism and caution around McMillan Shakespeare, it makes sense to move quickly and weigh both sides of the story using the 4 key rewards and 2 important warning signs.
Looking for more investment ideas beyond McMillan Shakespeare?
If you only stop at McMillan Shakespeare, you risk missing other stocks that could suit your goals. Use the Simply Wall St Screener to broaden your opportunity set.
- Target stronger income potential by reviewing a hand picked 8 dividend fortresses that already screens for yield and fundamentals.
- Zero in on value opportunities by scanning through a focused 10 high quality undervalued stocks that highlights quality businesses at prices below some estimates of worth.
- Prioritise resilience by checking a curated 14 resilient stocks with low risk scores that already filters for sturdier balance sheets and lower overall risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com